Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3iZGQcY
via IFTTT